Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Heart, Lung, and Blood Institute (NHLBI).
Recruitment status was  Recruiting
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
First received: July 2, 2009
Last updated: August 14, 2009
Last verified: July 2009
The Lung HIV goal is to facilitate the data and specimen collection efforts of eight individual HIV and pulmonary studies that operate under the direction of the NHLBI. The Lung HIV study will build on existing studies to facilitate the start-up of new projects to further the understanding of the relationship between pulmonary disease and HIV infection.

Condition Intervention
HIV Infections
Behavioral: Smoking Cessation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Outcome Measures:
  • To develop and evaluate a specialized smoking cessation intervention for the treatment of nicotine dependence in HIV-seropositive smokers. [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To examine the effects of smoking cessation on the course of lung function decline, the prevalence of respiratory symptoms and the occurrence/progression of emphysema in a cohort of HIV-seropositive individuals. [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 365
Study Start Date: September 2007
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Medication
Patients will be offered medication and lifestyle counseling to assist them with smoking cessation
Behavioral: Smoking Cessation
The smoking cessation treatment will include 12 weeks of varenicline treatment and proactive telephone counseling.
Other Name: Bupropion SR, Chiantix

Detailed Description:

The Lung HIV Study was established to examine a broad range of separate yet overlapping pulmonary complications being studied at eight separate Clinical Sites. A collection of datasets and biological specimens will be created for use during this project as well as for future investigations. The program is structured to facilitate both the development of these shared resources and the completion of the individual projects. Results of these efforts will be disseminated through publication in leading medical journals.

The concept of the Lung HIV study was developed by NHLBI to efficiently support multiple R01 efforts while simultaneously creating a shared database and specimen repository. The Lung HIV program will build on the knowledge and experience from existing studies and facilitate the start-up of new studies to further the understanding of the relationship between pulmonary disease and HIV infection. The Lung HIV mission is to achieve a clear understanding of the clinical manifestations of HIV-associated pulmonary complications by fostering multidisciplinary research collaboration and establishing a high quality centralized specimen repository with an associated clinical dataset based on shared definitions. All but one study are cross-sectional or cohort designs. One clinical trial is listed below.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

Men and women at the ACTU will be eligible to participate if they meet four criteria: (a) 18 years of age and older; and (b) diagnosis of HIV; and (c) self-reported smoking on a daily basis; and (d) provide informed written consent.

Exclusion criteria

Persons who meet one or more of the following criteria will be excluded from the study: (a) persons with active psychosis or impaired mental status as judged by the clinic staff and confirmed with a Mini-Mental Status Exam); (b) unable to understand spoken English; (c) age less than 18 years.

Rationale: Persons with cognitive impairment may participate in the study if they are able to provide consent and answer questionnaire questions. No reason is identified to exclude persons with this characteristic. No special risks are posed to cognitively impaired persons who are able to provide consent. Persons who have active psychoses or impaired mental status as judged by the clinic staff and confirmed with a Mini-Mental Status Exam are not able to provide informed written consent and are unlikely to benefit from the treatment. These persons will be referred to appropriate mental health services and invited to participate when their mental status has improved.

Persons who are unable to understand spoken English would not be able to complete the assessments or benefit from the treatments. Less than 1% of the clinic population will be excluded on this basis. However, persons excluded from the study on this basis will be referred for standard smoking cessation treatment delivered in their native tongue. These community resources may be identified through the Ohio State University Nursing Center for Tobacco Intervention.

Younger adolescents (<18 years) will not be invited to participate in the study because we believe that they require treatments that are qualitatively different from those designed for older adolescents and adults. The treatments that will be evaluated in the proposed research are well suited to older adolescents and adults, but not developmentally tailored to younger adolescents. Less than 1% of the clinic population will be excluded on this basis. Most HIV+ children living in Columbus, Ohio receive HIV medical care through the F.A.C.E.S. outpatient clinic at Columbus Children's Hospital. Standard, age appropriate, smoking cessation treatment is available through the Health and Wellness Center at Columbus Children's Hospital. In the unlikely circumstance that a child <18 years of age wishes to participate in the proposed study, s/he will be referred to Health and Wellness Center at Children's Hospital for treatment or the Ohio State University Nursing Center for Tobacco Intervention for age appropriate smoking cessation community resources.

Pregnant women may not be included as subjects. While smoking during pregnancy is an important modifiable cause of poor pregnancy outcomes, little information is available on the safety or efficacy of varenicline. Therefore, participants who are pregnant will be excluded as subjects. Also, women who are breast-feeding will be excluded.

Other persons who are unable to use varenicline will be allowed to participate in the study but will not receive the varenicline component of treatment. A history and physical examination will be conducted as a component of the baseline evaluation.

People that have kidney problems or undergo kidney dialysis will not take the study drug, but will be given the option to take nicotine replacement therapy.

All persons excluded from the study will have the opportunity to receive smoking cessation treatment. We will provide referrals for treatment as clinically indicated.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00933595

Contact: Bruce Thompson, PhD 443-435-0663 bthompson@c-tasc.com
Contact: Kate Burkhardt, CCRP 410-464-4197 kburkhardt@c-tasc.com

United States, California
University of California-San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Laurence Huang, MD    415-476-4082 ext 406    lhuang@php.ucsf.edu   
Contact: Anuradha Subramanian    415-206-6466    SubramanianA@php.ucsf.edu   
Principal Investigator: Laurance Huang, MD         
United States, Colorado
University of Colorado- Health Science Center Recruiting
Denver, Colorado, United States, 80262
Contact: Sonia Flores, PhD    303-724-6084    sonia.flores@ucdenver.edu   
Contact: Robert Shelton    720-281-8156    Robert.Shelton@ucdenver.edu   
United States, Connecticut
VA Connecticut Healthcare System Recruiting
West Haven, Connecticut, United States, 06516
Contact: Kristina Crothers, MD    203-932-5711 ext 5491    Kristina.Crothers@yale.edu   
Contact: Cyndi Frank    203-785-6939    cyndi.frank@yale.edu   
Principal Investigator: Kristina Crothers, MD         
United States, Maryland
Johns Hopkins University, Bloomberg School of Medicine Active, not recruiting
Baltimore, Maryland, United States, 21205
Johns Hopkins University, Department of Medicine Recruiting
Baltimore, Maryland, United States, 21231
Contact: Richard Chaisson, MD    410-955-1755    rchaiss@jhmi.edu   
Contact: Grace Barnes    410-614-3812    glbarnes@jhmi.edu   
Principal Investigator: Richard Chaisson, MD         
United States, New York
New York University School of Medicine Recruiting
New York, New York, United States, 10016
Contact: Maura Laverty    212-263-8905    Maura.Laverty@nyumc.org   
Contact: Dawn Walter    212-263-6502    Dawn.Walter@nyumc.org   
Principal Investigator: William Rom, MD, MPH         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Philip Diaz, MD    614-247-7707    Philip.Diaz@osumc.edu   
Contact: Janice Drake    614-366-2287    Janice.Drake@osumc.edu   
United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Alison Morris, MD, MS    412-692-2210    morrisa@upmc.edu   
Contact: Lorrie Lucht    412-805-0029    luchtla@upmc.edu   
Principal Investigator: Alison Morris, MD, MS         
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Study Director: Hannah Peavy, MD NHLBI Project Officer
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bruce Thompson, PhD, Clinical Trials and Surveys Corp (C-TASC)
ClinicalTrials.gov Identifier: NCT00933595     History of Changes
Other Study ID Numbers: 652  1R01HL09033-01  R01HL090312  R01HL090483  R01HL090316  R01HL090313  R01HL090335  R01HL090480  R01HL090339  R01HL090342 
Study First Received: July 2, 2009
Last Updated: August 14, 2009
Health Authority: United States: Federal Government

Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):

Additional relevant MeSH terms:
Communicable Diseases
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

ClinicalTrials.gov processed this record on August 25, 2016